Clinical trials: Immunoglobulin
Acne Vulgaris
Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris
This is a 91-day phase II, open label trial of the true human monoclonal antibody RA-18C3 in subjects with moderate to severe acne vulgaris. Ten (10) subjects will receive RA-18C3 via subcutaneous injection.
- Trial name
- NCT01474798
- Testing
- RA-18C3
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Janssen Research & Development, LLC
SLE, Systemic Sclerosis
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with active SLE, SSc, AAV, IIM, NMOSD, MS…
- Conditions
- SLE, Systemic Sclerosis, IIM, NMOSD
- Trial name
- NCT06775912
- Testing
- RD06-05 CART Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Amyloidosis; Systemic
A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis
This is a single center Phase 1 study is to evaluate the biodistribution of radiolabeled AT-03 in patients with systemic amyloidosis.
- Trial name
- AT03-001 (NCT05201911)
- Testing
- 124I-AT03
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Attralus, Inc.
Neoplasms
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968…
- Trial name
- NCT06150157
- Testing
- JNJ-88549968, Ruxolitinib, Momelotinib
- Where
- 45 sites in United States, Canada and 8 more
- Volunteers
- 300 people
- Sponsor
- Janssen Research & Development, LLC
Systemic Lupus Erythematosus
A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.
Anifrolumab Study of Treatment Effectiveness in the Real World (ASTER) study will collect real world data to obtain a good understanding of the (sustained) clinical effect and patient quality of life outcomes among diagnosed SLE…
- Trial name
- ASTER (NCT05637112)
- Testing
- None (Observational study)
- Where
- 74 sites in Austria, Belgium and 7 more
- Volunteers
- 551 people
- Sponsor
- AstraZeneca
Acellular Pertussis, Tetanus
Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.
To evaluate the immunogenicity, persistence of antibodies and reactogenicity of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX), when administered to subjects 18-20 months old, compared with not giving a booster DTP vaccine…
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00544271
- Testing
- INFANRIX, BOOSTRIX, HAVRIX
- Where
- Australia
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma (HCC), Solid Tumors
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
Researchers are studying a new potential treatment for liver cancer or other select solid cancers. To do this, researchers have developed a protein, called a monoclonal antibody, which can find and attach itself to another…
- Trial name
- NCT06345001
- Testing
- BAY3630942, BAY3547922
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Bayer
Asthma
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe.
- Trial name
- AIM4:Next Step (NCT06572228)
- Testing
- dupilumab, ICS/LABA
- Where
- 77 sites in United States, Canada and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Bone Tumor
Phase Ⅰ Clinical Study Protocol of GB223 Monoclonal Antibody Injection
The primary objective of this study is to evaluate the safety, tolerability and pharmacokinetic (PK) profiles of single dose of GB223 in healthy subjects; the secondary objective is to evaluate the immunogenicity and…
- Trial name
- NCT04178044
- Testing
- GB223,7mg/kg, GB223,21mg/kg, GB223,63mg/kg
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Genor Biopharma Co., Ltd.
Rabies Infection
Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age
Demonstrate non-inferiority of the immune response between new versus the currently recommended intradermal regimens of rabies vaccine when administered with or without rabies immunoglobulins in healthy subjects ≥ 1 years of age.
- Trial name
- NCT02177032
- Testing
- Rabies vaccine, Rabies vaccines + Rabies immunoglobulins
- Where
- 6 sites in Philippines, Thailand
- Volunteers
- 885 people, healthy volunteers welcome
- Sponsor
- Novartis
COVID-19
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
This study is designed to evaluate three dose levels of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) (COVID-HIGIV) for safety and pharmacokinetics (PK) in healthy adults.
- Trial name
- NCT04661839
- Testing
- COVID-HIGIV
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Rhinitis, Allergic, Respiratory Tract Infections
Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels
Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts and their…
- Conditions
- Rhinitis, Allergic, Respiratory Tract Infections, Allergy, Allergic Asthma
- Trial name
- NCT04389034
- Testing
- Pollinex Quattro with tree- and grass pollen extracts and their mixtures
- Where
- Germany
- Volunteers
- 113 people
- Sponsor
- Allergy Therapeutics
Breast Cancer
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic Breast Cancer will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated…
- Trial name
- NCT05160545
- Testing
- GNC-035
- Where
- 6 sites in China
- Volunteers
- 36 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Bladder Cancer
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or…
- Trial name
- NCT02302807
- Testing
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Docetaxel, Paclitaxel
- Where
- 217 sites in United States, Australia and 27 more
- Volunteers
- 931 people
- Sponsor
- Hoffmann-La Roche
Non-Squamous Non-Small Cell Lung Cancer
Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer
This is a randomized, open-label, multicenter, phase 2 study comparing Paclitaxel/Carboplatin with or without bavituximab in patients that have previously untreated locally advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT01160601
- Testing
- Paclitaxel / Carboplatin, bavituximab
- Where
- 40 sites in United States, Georgia and 3 more
- Volunteers
- 86 people
- Sponsor
- Peregrine Pharmaceuticals
Asthma
Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma
The aim of this study is to evaluate the expression of IgE high affinity receptors (the part of the cell associated with allergic response) in patients suffering from uncontrolled severe asthma despite long term treatment with…
- Trial name
- NCT00454051
- Testing
- Omalizumab
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Smallpox Vaccine Adverse Reaction
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
- Trial name
- NCT01158157
- Testing
- ACAM2000
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
PROC, Platinum Resistant Ovarian Cancer
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors.
- Conditions
- PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT07470853
- Testing
- HWK-016, MUCIN-16-targeted ADC, Bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 265 people
- Sponsor
- Whitehawk Therapeutics, Inc.
Neoplasms
GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)
This is a first time in human (FTIH), open-label, non-randomized, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of GSK3174998…
- Trial name
- NCT02528357
- Testing
- GSK3174998, Pembrolizumab
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline
Primary Immunodeficiency Diseases (PID)
Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients
The study duration for individual patients will be up to 55 weeks for the 4-weekly and 3- weekly schedule of the treatment which includes 3 weeks for screening, 48 weeks for Study Medication administration and 4 weeks for…
- Trial name
- VBPL-IVIGP3 (NCT07017036)
- Testing
- IVIG-VImmune, IVIG-Immuglo
- Where
- 2 sites in India
- Volunteers
- 44 people
- Sponsor
- Virchow Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.